The latest news from academia, regulators
research labs and other things of interest
Posted: November 16, 2009
NanoViricides, Inc. to Present at the Nano and Green Tech 2009 Conference
(Nanowerk News) NanoViricides, Inc., announced today that the Company's President, Anil R. Diwan, PhD, has been invited to give a talk at the Nano and Green Tech 2009 Conference on November 18, 2009. The Conference is being held in conjunction and partnership with Chem Show 2009 (http://www.chemshow.com) at the Javits Convention Center in New York City from Nov 17 through 19, 2009.
Dr. Diwan will be speaking in the session entitled "The Intersection of Nanotechnology and Biology". He will focus on the nanoviricide™ technology platform, explaining the "Find-Encapsulate-Destroy" antiviral strategy. He will also provide a general overview of the Company's major product platform including the pan-influenza nanoviricide, FluCide(™), anti-HIV nanoviricide HIVCide™, the nanoviricide eye antiviral drug candidate, and the Herpes cold sores and genital herpes drug candidate.
In addition, Dr. Diwan will discuss the Company's novel broad-spectrum nanoviricides as a low cost approach against Neglected Tropical Diseases (NTD's) such as Dengue viruses, Rabies virus, and Rotavirus among others. Although long thought of as a problem of developing countries in tropical climates, many of the NTD's are moving into the developed world as well. To underscore the importance of having treatments available, it was recently reported that Key West's health officials were urging people to take precautions against dengue fever. This was after survey results showed that 41 percent of local residents tested positive for antibodies associated with the disease. The survey was conducted by researchers from the Centers for Disease Control and Prevention and the Florida Department of Health (http://www.miamiherald.com/news/florida/AP/v-print/story/1332029.html).
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.